US › Healthcare

Karyopharm Therapeutics Inc (KPTI)

US · Healthcare · Biotechnology

$1.79+5.29%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$33.4M

Revenue YoY

-11.9%

Net profit

$-67.0M

EPS

$-2.32

EPS estimate

$-1.53

Net margin

-200.5%

EPS came in at -2.32 against a street estimate of -1.53 — a miss of 51.6%.

Key statistics

Market cap

$36.7M

Forward P/E

0.0

P/B

12.05

Book value

$-14.56

EPS (TTM)

$-13.74

52-week high

$10.99

52-week low

$1.24

50-day MA

$4.94

200-day MA

$7.09

Beta

0.95

Analyst view

Analysts rate Karyopharm Therapeutics Inc a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $7.25.

Shareholding

Insiders

4.67%

Institutions

97.98%

Largest institutional holders

Fund	Stake
COMMODORE CAPITAL LP	8.60%
RA Capital Management, LLC	8.45%
T. Rowe Price Investment Management,Inc.	6.80%
Adage Capital Partners Gp LLC	6.71%
The Goldman Sachs Group Inc	4.18%
Catalio Capital Management, LP	4.15%
Avidity Partners Management LP	4.08%
Vanguard Capital Management, LLC	3.26%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Karyopharm Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.